The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. | Final results from IMPROVE A randomized controlled open-label two-arm cross-over phase IV study to determine patients preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive HER2-negative breast cancer